[32] Russell Russell S S Bennett Bennett J J Wellman Wellman JA JA et al et al 2017 2017 Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial Lancet 390(10097) Lancet 390(10097) 849 849 860 860 doi:10.1016/S0140-6736(17)31868-8 doi:10.1016/S0140-6736(17)31868-8. The gene discussed is RPE65; the disease is inherited retinal dystrophy.